Play all audios:
Loading...
In Wednesday's Investor's Corner, IBD emphasized the importance of examining the quality and week-to-week action of a base. Alexion Pharmaceuticals (ALXN), with its strong rally
since 2010 and excellent fundamentals, deserves close examination, even with the elevated risk of its late-stage base status. The stock peaked at 95.01 on March 26, then formed what appears
to be a 12-week flat…